Anti-Coagulation Factor X (F10) Rabbit Polyclonal Antibody for WB, IF/ICC, ELISA - P00742

Core Product Specifications and Parameters

Biological Background: Coagulation Factor X Function and Localization

• Factor X (F10), also known as Stuart factor or Stuart-Prower factor, is a vitamin K-dependent glycoprotein synthesized in the liver and secreted into plasma as a zymogen.
• Upon activation, factor Xa converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid, a critical step in the coagulation cascade. Related references: PMID:22409427, PMID:39880037
• Factor Xa activates protease-activated receptors (PARs) F2R, F2RL1 and F2RL2, triggering pro-inflammatory signaling. It up-regulates expression of PARs and stimulates production of cytokines such as MCP-1/CCL2, IL6, TNF, IL-1β, IL-8, and IL-18 in endothelial cells and cardiac/atrial tissues. Related references: PMID:24041930, PMID:30568593, PMID:34831181, PMID:35738824, PMID:9780208
• Factor Xa induces expression of adhesion molecules (ICAM1, VCAM1, SELE) and increases phosphorylated ERK1/2 and NF-κB activation, promoting endothelial inflammation and a pro-fibrotic phenotype in atrial tissues. Related references: PMID:24041930, PMID:35738824, PMID:9780208
• In dermal fibroblasts, factor Xa promotes wound healing via a PAR-2/F2RL1-dependent mechanism, enhancing pro-inflammatory and pro-fibrotic responses. Related references: PMID:18202198
• Factor Xa also activates barrier-protective signaling in endothelial cells through PAR-2/F2RL1 cleavage and up-regulates plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues. Related references: PMID:22409427, PMID:24041930
• The protein undergoes extensive post-translational modifications, including vitamin K-dependent γ-carboxylation, hydroxylation, and forms multiple disulfide bonds within its EGF-like domains, characteristic of the serine protease family.
• Keywords: Blood coagulation, hemostasis, hydrolase, serine protease, secreted, zymogen, calcium, EGF-like domain, gamma-carboxyglutamic acid, disease variant.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 235-488 of human F10, covering part of the catalytic domain. This recombinant protein fragment is expected to generate antibodies recognizing both the zymogen and active forms.
• For Western blotting, a band around 55 kDa is anticipated, but note that glycosylation may cause migration differences. Consider validating in relevant human and mouse plasma or tissue lysates.
• For IF/ICC, appropriate fixation and permeabilization protocols should be optimized for the target cell type. The secreted nature of F10 may require stimulation with coagulation triggers for detection in cell culture.
• In ELISA applications, this polyclonal antibody can serve as a capture or detection reagent; pair with a monoclonal antibody for sandwich ELISA development in hemostasis research.
• Given cross-reactivity with mouse, this antibody may be useful in murine models of thrombosis or inflammation; however, confirm species-specific reactivity in your experimental system.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio empowers diagnostic manufacturers and research labs with comprehensive access to IVD raw materials. This anti-F10 polyclonal antibody is part of our expanding portfolio for hemostasis, thrombosis, and inflammation research. Beyond individual antibodies, we offer validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and rare target raw-material sourcing to accelerate your assay development from concept to clinic.